| Literature DB >> 1782075 |
G Schwartsmann1, E Sprinz, M Kronfeld, J Vinholes, E Sander, M Zampese, R Preger, L Kalakun, A L Brunetto.
Abstract
Antitumour activity of cytotoxic agents, evaluated in patients with AIDS-related Kaposi's sarcoma (KS), is about 30-80%. However, responses are mostly partial and short. Experience with etoposide is similar. Teniposide has a longer elimination half-life and superior antitumour activity compared with etoposide in some experimental models. Thus a phase II trial was done in 25 patients with AIDS-related KS. Teniposide was given by 60-min infusion at 360 mg/m2 every 3 weeks. 10 (40%) showed a partial response, median duration of 9 (6-20) weeks. The main side-effects were leukopenia, thrombocytopenia, nausea and vomiting, alopecia and mucositis.Entities:
Mesh：
Substances：
Year: 1991 PMID： 1782075 DOI： 10.1016/0277-5379(91)90434-f
Source DB: PubMed Journal: Eur J Cancer ISSN： 0959-8049 Impact factor: 9.162